Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial
F. Penault-Llorca (Lead / Corresponding author), F. Dalenc, S. Chabaud, P. Cottu, D. Allouache, D. Cameron, J. Grenier, L. Venat Bouvet, A. Jegannathen, M. Campone, M. Debled, A. C. Hardy-Bessard, S. Giacchetti, P. Barthelemy, L. Kaluzinski, A. Mailliez, M.-A. Mouret-Reynier, E. Legouffe, A. Cayre, M. MartinezC. Delbaldo, D. Mollon-Grange, E. J. Macaskill, M. Sephton, L. Stefani, B. Belgadi, M. Winter, H. Orfeuvre, M. Lacroix-Triki, H. Bonnefoi, J. Bliss, J.-L. Canon, J. Lemonnier, F. Andre, T. Bachelot
Research output: Contribution to journal › Article › peer-review
40Downloads
(Pure)
Fingerprint
Dive into the research topics of 'Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial'. Together they form a unique fingerprint.